09 January 2024
Futura Medical plc
Appointment of Roy Davis as Non-Executive Director
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), the pharmaceutical company developing innovative sexual health products, today announces the appointment of Roy Davis as a Non-Executive Director with immediate effect.
Roy brings a wealth of commercial experience in medical devices companies and has a proven track record of successfully scaling companies and delivering substantial value for shareholders. He has held leadership positions at a number of publicly quoted med tech companies, including CEO of Optos plc, a leading retinal imaging device manufacturer, from 2008 to 2016 until its sale to Nikon for £259m in February 2015. From 2007 to 2008, Roy was CEO of Gyrus Group plc, a leader in minimally invasive surgery and visualisation, until its acquisition by Olympus Corporation in 2008 for $1.9 billion.
He is currently Non-Executive Chair at LungLife AI plc, Foster and Freeman (the trading name of the Galton group of companies) and Rair Health Ltd and was until recently, Non-Executive Chair at Medica Group plc until its acquisition by IK Partners for £269 million earlier this year. On 7 December it was announced that Roy will become a Non-Executive Director and Chair Designate of Inspiration Healthcare Group plc with effect from 25 January 2024.
Jeff Needham, Chairman of Futura Medical said: "Roy brings with him significant commercial expertise and a proven track record of creating substantial shareholder value. His appointment will add to the depth and breadth of experience of the Futura Board as we continue to monetise our key asset, Eroxon, move towards profitability, and deliver on our strategy."
Roy Davis, said: "I am delighted to be joining the Board of Futura. The Company is providing novel solutions in the sexual health sector and has exciting opportunities ahead of it. I look forward to working with the Board and Executive Team to help execute the strategy and deliver shareholder value."
In accordance with Schedule 2 (g) of the AIM Rules for Companies, Gordon Roy Davis (aged 67 years) holds/has held the following directorships/partnerships in the last five years:
| Current directorships/partnerships | Previous directorships/partnerships (last five years) |
| LungLifeAI, Inc Rair Health Limited Galton Bidco Limited Galton Midco Limited Galton Topco Limited Galton Tradeco Limited | Medica Group plc Edinburgh Molecular Imaging Limited |
In addition to the above, Roy Davis was a director of C-Quential Limited until his resignation on 28 February 2001. The company entered into a creditors voluntary liquidation on 11 February 2002 and was subsequently dissolved on 18 August 2007.
Roy Davis currently holds no ordinary shares in the Company.
There are no further disclosures to be made under Schedule 2(g) of the AIM Rules for Companies.
ENDS
For further information please contact:
Futura Medical plc
James Barder, Chief Executive Officer
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
Nominated Adviser and Sole Broker:
Liberum
Phil Walker/ Ben Cryer/Nikhil Varghese
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Nick Bastin / Jonathan Edwards / Elena Bates
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative sexual health products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
MED3000 is Futura's topical gel formulation that is a novel treatment for erectile dysfunction (ED) through a unique evaporative mode of action and is sold in Europe and the UK under the brand name Eroxon®. Futura has conducted two Phase 3 studies using MED3000 in ED; the FM57 study which enabled Futura to be granted a CE Mark in 2021 and FM71 which enabled Futura to be granted US marketing authorisation. Both studies demonstrated that MED3000 presents an effective clinically proven treatment for ED with a rapid speed of onset and a favourable benefit versus risk profile ideally suited for an 'Over the Counter' classification.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
